Cloudbreak Pharmaceutical
Latest round
- Series C
Last raised
- Jan 2022
Total raised
- $171M
Investors
- 15
About Cloudbreak Pharmaceutical
Based in Irvine, US and established in 2015, Cloudbreak Pharmaceutical is a pharmaceutical company that provides ocular drug development to treat eye diseases. The company developed drugs to treat eye diseases and drug candidates was approved, completed proof-of-concept (POC) phase II clinical, and carried out phase III clinical trials, product registration, and commercialization. The company takes contract research organizations (CRO) for non-clinical, chemistry, manufacturing and controls (CMC) and clinical development to realize maximize capital for drug development. The company developed ocular drug to treat eye diseases, including pterygium, meibomian gland dysfunction associated dry eye disease, pinguecula, glaucoma filtration surgery, wet age related macular degeneration, and myopia progression. The company's product pipeline includes CBT-001, CBT-006, CBT-004, CBT-007, CBT-005, CBT-009. CBT-001 is a potent multi-kinase inhibitor. CBT-006 is a molecule that can sequester cholesterol. CBT-009 is a ophthalmic formulation of atropine. The CBT-001, CBT-006, and CBT-004 is in clinical study phase II. The company plans to promote clinical study, registration, and commercialization of multiple product pipelines, to build GMP plant, and to introduce talents. The company generates revenue from pharmaceutical partnerships, licensing agreements, milestone payments, and anticipates future income from drug commercialization, especially through proprietary ophthalmic products advancing through late-stage trials.10 per share on the Hong Kong Exchanges and Clearing Limited, under ticker 2592.
Who invested in Cloudbreak Pharmaceutical
15 investors across 3 rounds
See all investors in Cloudbreak Pharmaceutical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cloudbreak Pharmaceutical
Who invested in Cloudbreak Pharmaceutical?
Cloudbreak Pharmaceutical has 15 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cloudbreak Pharmaceutical raised?
Cloudbreak Pharmaceutical has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cloudbreak Pharmaceutical last raise money?
Cloudbreak Pharmaceutical's most recent round on record is a Series C, in Jan 2022.
What does Cloudbreak Pharmaceutical do?
Based in Irvine, US and established in 2015, Cloudbreak Pharmaceutical is a pharmaceutical company that provides ocular drug development to treat eye diseases.
Where is Cloudbreak Pharmaceutical headquartered?
Cloudbreak Pharmaceutical is headquartered in Irvine, US.
Which VCs invest in companies like Cloudbreak Pharmaceutical?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cloudbreak Pharmaceutical's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Cloudbreak Pharmaceutical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.